Thomas Wilder Sells 360 Shares of Penumbra, Inc. (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 360 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $266.93, for a total transaction of $96,094.80. Following the completion of the sale, the director now owns 4,692 shares of the company’s stock, valued at approximately $1,252,435.56. This represents a 7.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Thomas Wilder also recently made the following trade(s):

• On Monday, March 31st, Thomas Wilder sold 360 shares of Penumbra stock. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80.

Penumbra Stock Performance

PEN opened at $262.37 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The firm has a market cap of $10.11 billion, a P/E ratio of 771.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The business’s fifty day moving average is $274.48 and its 200-day moving average is $245.61.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. The firm had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. Sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

PEN has been the topic of several research analyst reports. Bank of America began coverage on Penumbra in a research note on Friday, March 14th. They issued a “buy” rating and a $320.00 price objective on the stock. Wells Fargo & Company increased their price target on Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, February 19th. UBS Group lifted their price objective on shares of Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Truist Financial increased their price objective on shares of Penumbra from $285.00 to $325.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Finally, StockNews.com downgraded shares of Penumbra from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Penumbra has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its holdings in shares of Penumbra by 893.5% in the 1st quarter. Versant Capital Management Inc now owns 308 shares of the company’s stock valued at $82,000 after purchasing an additional 277 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Penumbra by 74.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,115 shares of the company’s stock worth $740,000 after buying an additional 1,332 shares during the last quarter. Employees Retirement System of Texas boosted its stake in Penumbra by 31.9% in the fourth quarter. Employees Retirement System of Texas now owns 5,273 shares of the company’s stock valued at $1,252,000 after buying an additional 1,274 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in Penumbra in the fourth quarter valued at about $760,000. Finally, Polar Asset Management Partners Inc. raised its stake in Penumbra by 10.5% during the fourth quarter. Polar Asset Management Partners Inc. now owns 122,126 shares of the company’s stock worth $29,002,000 after acquiring an additional 11,605 shares in the last quarter. 88.88% of the stock is owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.